1. Home
  2. TTRX vs TMCI Comparison

TTRX vs TMCI Comparison

Compare TTRX & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

SELL

Current Price

$11.11

Market Cap

298.8M

Sector

Health Care

ML Signal

SELL

Logo Treace Medical Concepts Inc.

TMCI

Treace Medical Concepts Inc.

HOLD

Current Price

$4.10

Market Cap

292.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTRX
TMCI
Founded
2015
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
298.8M
292.0M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
TTRX
TMCI
Price
$11.11
$4.10
Analyst Decision
Strong Buy
Hold
Analyst Count
2
5
Target Price
★ $25.00
$5.50
AVG Volume (30 Days)
145.0K
★ 217.5K
Earning Date
11-25-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $212,690,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$900.00
$6.88
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 1.59
52 Week Low
$2.57
$1.17
52 Week High
$16.45
$7.08

Technical Indicators

Market Signals
Indicator
TTRX
TMCI
Relative Strength Index (RSI) 42.42 43.08
Support Level $9.02 $3.84
Resistance Level $14.39 $4.67
Average True Range (ATR) 1.25 0.24
MACD -0.41 -0.05
Stochastic Oscillator 1.09 39.96

Price Performance

Historical Comparison
TTRX
TMCI

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

About TMCI Treace Medical Concepts Inc.

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.

Share on Social Networks: